Valuation : NEOVACS

Market Cap 4.09K 4.75K 3.83K 3.5K 6.59K 454K 6.61K 45.49K 17.75K 229K 17.82K 17.43K 759K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -233K -188K -172K -324K -22.29M -325K -2.24M -872K -11.25M -876K -857K -37.31M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day+0.91%
1 week-34.45%
Current month-45.21%
1 month-45.21%
3 months-90.00%
6 months-97.33%
Current year-99.54%
1 week 0.38
Extreme 0.3824
0.62
1 month 0.38
Extreme 0.3824
1.43
Current year 0.38
Extreme 0.3824
267
1 year 0.38
Extreme 0.3824
6,780
3 years 0.38
Extreme 0.3824
32,000,000
5 years 0.38
Extreme 0.3824
351,920,000
10 years 0.38
Extreme 0.3824
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 30/09/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 27/05/2003
Director/Board Member - 30/04/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
27/02/21 Sell

Chief Executive Officer

2,505,144 1.3796%
23/02/21 Sell

Chief Executive Officer

6,391,053 3.5196%
23/02/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%-34.45%-99.99%-100.00% 73.17K
-0.94%-1.67%+1.23%+18.22% 50.47B
-2.36%-3.71%+415.36%+499.71% 44.56B
-0.85%-0.55%+40.86%+16.25% 43.08B
-2.95%-4.25%+7.26%+71.60% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.09%-4.77%+24.74%+118.47% 16.77B
+5.71%+5.77% - - 16.28B
-0.36%-1.58%+10.96%+26.85% 14.58B
-0.56%-3.47%+78.75%+39.36% 13.92B
Average -0.28%-4.77%+55.40%+82.08% 27.46B
Weighted average by Cap. -0.95%-1.21%+88.85%+121.57%

Financials

2023 2024
Net sales 533K 619K 500K 457K 860K 59.16M 863K 5.93M 2.32M 29.86M 2.32M 2.27M 99.03M 434K 504K 407K 371K 700K 48.13M 702K 4.83M 1.88M 24.3M 1.89M 1.85M 80.56M
Net income -8.74M -10.15M -8.2M -7.48M -14.1M -970M -14.14M -97.26M -37.95M -490M -38.1M -37.27M -1.62B -32.91M -38.2M -30.86M -28.17M -53.07M -3.65B -53.24M -366M -143M -1.84B -143M -140M -6.11B
Net Debt -237K -274K -222K -202K -381K -26.23M -383K -2.63M -1.03M -13.24M -1.03M -1.01M -43.91M -205K -238K -192K -176K -331K -22.75M -332K -2.28M -890K -11.48M -894K -874K -38.07M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
31/08/26 0.4000 +0.91% 28,229
28/08/26 €0.3964 -0.92% 37,658
27/08/26 €0.4001 -4.74% 51,473
26/08/26 €0.4200 -23.64% 93,428
25/08/26 €0.5500 -9.87% 44,805
  1. Stock Market
  2. Stocks
  3. ALNEV Stock